Table 1.
Patient demographics and clinical characteristics
|
Characteristic |
All patients | Primary cohort | Validation cohort | ||
|---|---|---|---|---|---|
| No(%) | No. (%) | No. (%) | P | ||
| Total | 690 | 460 | 230 | ||
| Gender | 0.045 | ||||
| Male | 505(73.2%) | 348(75.7%) | 157(68.3%) | ||
| Female | 185(26.8%) | 112(24.3%) | 73(31.7%) | ||
| Age(years) | 1.000 | ||||
| ≤45 | 345(75.7%) | 230(50.0%) | 115(50.0%) | ||
| >45 | 345(24.3%) | 230(50.0%) | 115(50.0%) | ||
| Tumor stage | 0.024 | ||||
| T1 | 41(5.9%) | 29(6.3%) | 12(5.2%) | ||
| T2 | 146(21.2%) | 82(17.8%) | 64(27.8%) | ||
| T3 | 309(44.8%) | 217(47.2%) | 92(40.0%) | ||
| T4 | 194(28.1%) | 132(28.7%) | 62(27.0%) | ||
| Node stage | 0.523 | ||||
| N0 | 101(14.6%) | 64(13.9%) | 37(16.1%) | ||
| N1 | 270(39.1%) | 186(40.4%) | 84(36.5%) | ||
| N2 | 242(35.1%) | 164(35.7%) | 79(34.3%) | ||
| N3 | 77(11.2%) | 46(10.0%) | 30(13.0%) | ||
| TNM stage | 0.090 | ||||
| I | 19(2.8%) | 13(2.8%) | 6(2.6%) | ||
| II | 83(12.0%) | 46(10.0%) | 37(16.1%) | ||
| III | 324(47.0%) | 227(49.3%) | 97(42.2%) | ||
| IV | 264(38.3%) | 174(37.8%) | 90(39.1%) | ||
| Treatment | 0.024 | ||||
| Radiotherapy | 104(15.1%) | 59(12.8%) | 45(19.6%) | ||
| Chemoradiotherapy | 586(84.9%) | 401(87.2%) | 185(80.4%) | ||
| EBVDNA, copy/mL | 0.086 | ||||
| <103 | 311(45.1%) | 213(46.3%) | 98(42.6%) | ||
| 103~9999 | 150(21.7%) | 90(19.6%) | 60(26.1%) | ||
| 10 4~99999 | 127(18.4%) | 93(20.2%) | 34(14.8%) | ||
| 105~999999 | 64(9.3%) | 43(9.3%) | 21(9.1%) | ||
| ≥ 106 | 38(5.5%) | 21(4.6%) | 17(7.4%) | ||
| VCA-IgA | 0.427 | ||||
| <1:80 | 113(16.4%) | 72(15.7%) | 41(17.8%) | ||
| 1:80-1:320 | 416(60.3%) | 286(62.2%) | 132(57.4%) | ||
| ≥ 1:640 | 159(23.0%) | 102(22.2%) | 57(24.8%) | ||
| EA-IgA | 0.196 | ||||
| <1:10 | 207(30.0%) | 135(29.3%) | 72(31.3%) | ||
| 1:10-1:20 | 226(32.8%) | 161(35.0%) | 65(28.3%) | ||
| ≥1:40 | 257(37.2%) | 164(35.7%) | 93(40.4%) | ||
| LDH, U/L | 0.572 | ||||
| ≤161.6 | 339(49.1%) | 230(50.0%) | 109(47.4%) | ||
| >161.6 | 351(50.9%) | 230(50.0%) | 121(52.6%) | ||
| hs-CRP,mg/L | 0.106 | ||||
| ≤2.03 | 362(52.5%) | 231(50.2%) | 131(57.0%) | ||
| >2.03 | 328(47.5%) | 229(59.8%) | 99(43.0%) | ||
| ALB, g/L | 0.125 | ||||
| ≤43.40 | 349(50.6%) | 223(48.5%) | 126(54.8%) | ||
| >43.40 | 341(49.4%) | 237(51.5%) | 104(45.2%) | ||
| HLD-C, mmol/L | 0.936 | ||||
| ≤1.17 | 347(50.3%) | 232(50.4%) | 115(50.0%) | ||
| >1.17 | 343(49.7%) | 228(49.6%) | 115(50.0%) | ||
| ApoA-1, g/L | 0.063 | ||||
| ≤1.28 | 329(47.7%) | 231(50.2%) | 98(42.6%) | ||
| >1.28 | 361(52.3%) | 229(59.8%) | 132(57.4%) | ||
| HGB, g/L | 0.002 | ||||
| ≤139 | 375(54.3%) | 231(50.2%) | 144(62.6%) | ||
| >139 | 315(45.7%) | 229(59.8%) | 86(37.4%) | ||
| PLR | 0.872 | ||||
| ≤141.08 | 347(50.3%) | 230(50.0%) | 117(50.9%) | ||
| >141.08 | 343(49.7%) | 230(50.0%) | 113(49.1%) | ||
| NLR | 0.258 | ||||
| ≤2.60 | 356(51.6%) | 230(50.0%) | 126(54.8%) | ||
| >2.60 | 334(48.4%) | 230(50.0%) | 104(45.2%) | ||
| LMR | 0.809 | ||||
| ≤3.67 | 349(50.6%) | 231(50.2%) | 118(51.3%) | ||
| >3.67 | 341(49.4%) | 229(59.8%) | 115(48.7%) |